KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Interest & Investment Income (2023 - 2026)

Neogenomics filings provide 6 years of Interest & Investment Income readings, the most recent being $1.3 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income fell 65.79% to $1.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.6 million, a 61.75% decrease, with the full-year FY2025 number at $9.1 million, down 50.78% from a year prior.
  • Interest & Investment Income hit $1.3 million in Q1 2026 for Neogenomics, down from $1.5 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.8 million in Q4 2023 to a low of $1.3 million in Q1 2026.
  • Median Interest & Investment Income over the past 4 years was $4.3 million (2023), compared with a mean of $3.5 million.
  • Biggest five-year swings in Interest & Investment Income: rose 6.59% in 2024 and later crashed 66.55% in 2025.
  • Neogenomics' Interest & Investment Income stood at $4.8 million in 2023, then decreased by 10.67% to $4.3 million in 2024, then tumbled by 64.81% to $1.5 million in 2025, then dropped by 16.41% to $1.3 million in 2026.
  • The last three reported values for Interest & Investment Income were $1.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025) per Business Quant data.